Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease

Viraj C. Kariyawasam*, Christian P. Selinger, Peter H. Katelaris, D. Brian Jones, Charles McDonald, Gavin Barr, Grace Chapman, James Colliwshaw, Paul C. Lunney, Kate Middleton, Rosy R. Wang, Tony Huang, Jane Andrews, Rupert W. Leong

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)

Abstract

Background: Earlier introduction of immunomodulators (IM) thiopurine or methotrexate is advocated to improve Crohn's disease (CD) outcomes, but whether abdominal surgery can be prevented remains controversial. Methods: A specialist-referred cohort of CD was recruited from 1970 to 2009. Early IM use was defined as commencement of azathioprine or methotrexate within 3 years of CD diagnosis and adherence of at least 6 months. Propensity score matching was conducted to correct for confounders influencing early IM introduction. Outcomes of interest were rates of initial and recurrent major abdominal surgery for CD and their predictive factors. Results: A total of 1035 consecutive patients with CD (13, 061 patient-years) were recruited. The risk of first and recurrent major abdominal surgery at 1, 5, and 10 years were 17.5%, 28.4%, and 39.5% and 5.9%, 19.0%, and 33.3%, respectively. Early IM use increased over time from 1.3% to 55.3% (P < 0.0001) and was a significant independent predictor of lower rates of initial abdominal surgery (hazard ratio [HR], 0.45; 95% confidence interval [CI]< 0.35-0.69), recurrent abdominal surgery (HR, 0.44; 95% CI, 0.25-0.79) and perianal surgery (HR, 0.30; 95% CI, 0.16-0.56). Using propensity score matching, early IM significantly reduced surgical rates (HR, 0.54; 95% CI, 0.37-0.79). Number needed to treat to prevent a surgical event at 5 years from diagnosis and after initial surgery was 6.99 (95% CI, 5.34-11.95) and 8.59 (95% CI, 6.26-23.93), respectively. Conclusions: Early IM use with thiopurines or methotrexate was significantly associated with the reduced need for abdominal and perianal surgery in CD.

Original languageEnglish
Pages (from-to)1382-1390
Number of pages9
JournalInflammatory Bowel Diseases
Volume20
Issue number8
DOIs
Publication statusPublished - Aug 2014
Externally publishedYes

Keywords

  • Azathioprine
  • Crohn's disease
  • Immunomodulator
  • Mercaptopurine
  • Methotrexate
  • Outcome
  • Surgery
  • Thiopurine
  • Treatment

Fingerprint

Dive into the research topics of 'Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease'. Together they form a unique fingerprint.

Cite this